169 results
Page 5 of 9
424B5
mr57q9mt1fx3y
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
sze9w3s c1xkhr
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
8o8zq
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
0irabcx6yj8nlb
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
uxzafq82e5l sb0s
4 Nov 19
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
7:07am
8-K
EX-99.1
62rdbc3g55 z3f6n9
6 Aug 19
Results of Operations and Financial Condition
7:13am
8-K
EX-99.1
fw10 gjv7x
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
424B5
s84ye
10 May 19
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
9o8ab7
9 May 19
Results of Operations and Financial Condition
7:10am
DEFA14A
jk4sq561l4udc
19 Apr 19
Additional proxy soliciting materials
4:08pm
PRE 14A
d2f0a6chzy 4yvvlz7ok
2 Apr 19
Preliminary proxy
4:29pm
8-K
EX-99.1
vwm5fbl7
28 Feb 19
Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
7:22am
8-K
EX-10.2
v18ch uoo
18 Jan 19
Departure of Directors or Certain Officers
4:06pm